Bacterial resistance. A global public health problem with difficult solution by Fariña, Norma
 





Bacterial resistance. A global public health problem with difficult solution 
 
Just three years after large-scale commercialization of penicillin G started in 1945, the 
first therapeutic failures were described. While the emergence of antibiotic resistance is 
a natural phenomenon that occurs in microorganisms, this fact is mainly exacerbated 
by the inappropriate use of antimicrobials, poor quality of medicine, lack or deficient 
programs for the prevention and control of infections, weak capacity of laboratories to 
detect resistance, inadequate surveillance and regulation of antimicrobial use. 
Misuse of antibiotics is one of the most important factors determining the current 
alarming situation: use of antibiotics without prescriptions, inappropriate consumption 
time, non-compliance of administration schedules, and underdosing. On the other 
hand, many of our physicians make unnecessary prescriptions, especially for upper 
airway diseases, in most cases of viral etiologies or even in allergies. Based on studies 
about antibiotic use, upper airway cases are the pathologies in which antibiotics are 
more unnecessarily used. 
In our country, another point of concern is the deficiency of prevention and infection 
control programs, mainly for those of nosocomial origin. In health centers, especially in 
public hospitals, it is essential to promote consciousness of the importance as well as 
to monitor the compliance of simple, easy and inexpensive measure such as frequent 
hand washing; which can greatly reduce the frequency of hospital infections and thus, 
contribute to reduce antibiotic use in hospitals. 
The increased bacterial resistance, due to the selective pressure that represents the 
use of antibiotics on a large scale, especially in our hospitals, has led to the spread of 
strains with resistance mechanisms that often leave us with no alternatives for 
treatment of bacterial infections. Antimicrobial resistance reduces the chances of 
effective treatment of diseases, prolongs the agony of the patients and forces them to 
use expensive drugs, in addition to lengthen the time of hospitalization and increase 
the risk of mortality. 
Currently in Paraguay, the emergence of methicillin-resistant Staphylococcus aureus is 
among the most worrying resistances. For a long time, it was considered exclusively 
nosocomial but today it is a major cause of community-acquired infections. Until a few 
years ago, the antibiotic of choice for this bacterium responsible for surgical wounds 
and skin and soft tissue infections, was cephalexin; however, this antibiotic has no 
activity on meticillin-resistant Staphylococcus aureus. Neither beta-lactam antibiotics 
can be used to treat infections caused by this bacterium, not even in combination with 
beta-lactamase inhibitors (amoxicillin, sulbactam, tazobactam). 
Another group of widely spread bacteria is the gram-negative bacilli of the  
Enterobacteriaceae family, which have significantly increased their resistance, 
especially by easily spread mechanisms like the production of beta-lactamase type 
enzymes; which are of several types. Those of broad spectrum have the ability to 
hydrolyze first generation aminopenicillins, carboxipenicillins and cephalosporin, while 
those of extended spectrum inactivate third and even fourth generation 
cephalosporins. 
The increase of resistant-bacteria to carbapenem (imipenem, meropenem), both 
enterobacteria by KPC carbapenemase production and non-fermenting glucose gram-
negative bacilli by metallobetalactamese type carbapenemase production, 
impermeability, efflux, among others, especially in high complexity hospitals of our 
country, leave us only toxic and / or very costly therapeutic alternatives like colystin. 
The resistance to fluoroquinolones (norfloxacin, ciprofloxacin, levofloxacin) is also 
worrying because they are excellent antibiotics due to their pharmacokinetics and easy 
administration by oral via, but with the disadvantage of presenting cross resistance. 
We are losing these antibiotics, widely used in adult urinary tract infections as well as 
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in gastrointestinal infections, as an empirical therapy due to the current increasing 
resistance. 
We cannot fail to mention other factors that increase the magnitude of the problem, as 
the use of antibiotics in consumption agriculture and animals. 
The phenomenon of bacterial resistance is considered a global public health problem 
with difficult solution. While it is not possible to end the problem of antimicrobial 
resistance, it is possible to convert this growing threat into a manageable problem. 
At the World Health Assembly held in 2014, a consensus was reached about the need 
for a global action plan to fight antimicrobial resistance, involving countries from all 
regions. This plan points to raise awareness and education, optimize antimicrobial use, 
reduce infection incidence and resistant organism spreading, and ensure sustainable 
investment for the fight against antimicrobial resistance. 
Though science advances rapidly, very few pharmaceutical companies make 
investments for the search of antibiotics because they do not consider it profitable, 
since the misuse and abuse favor bacteria quickly find ways to evade antibiotics action. 
Consequently, no new family of antibiotics has been discovered in the last three 
decades.  
Let us contribute to preserve antibiotics for future generations. Each of us from our 
workplace, from our environment, we can provide a molehill to mitigate the problem. 
If we do not start to raise awareness of the problem of antimicrobial resistance and 
deal with it very soon we will be in danger of running out of treatment options for 
many bacterial infections. 
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